{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:24:43Z","timestamp":1787444683279,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016_A96"],"award-info":[{"award-number":["2016_A96"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016_A96"],"award-info":[{"award-number":["2016_A96"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271 SFB-TRR205"],"award-info":[{"award-number":["314061271 SFB-TRR205"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100015272","name":"Societ\u00e0 Italiana di Farmacologia","doi-asserted-by":"publisher","award":["Borsa"],"award-info":[{"award-number":["Borsa"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100015272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>FGF\/FGFR signaling regulates embryogenesis, angiogenesis, tissue homeostasis and wound repair by modulating proliferation, differentiation, survival, migration and metabolism of target cells. Understandably, compelling evidence for deregulated FGF signaling in the development and progression of different types of tumors continue to emerge and FGFR inhibitors arise as potential targeted therapeutic agents, particularly in tumors harboring aberrant FGFR signaling. There is first evidence of a dual role of the FGF\/FGFR system in both organogenesis and tumorigenesis, of which this review aims to provide an overview. FGF-1 and FGF-2 are expressed in the adrenal cortex and are the most powerful mitogens for adrenocortical cells. Physiologically, they are involved in development and maintenance of the adrenal gland and bind to a family of four tyrosine kinase receptors, among which FGFR1 and FGFR4 are the most strongly expressed in the adrenal cortex. The repeatedly proven overexpression of these two FGFRs also in adrenocortical cancer is thus likely a sign of their participation in proliferation and vascularization, though the exact downstream mechanisms are not yet elucidated. Thus, FGFRs potentially offer novel therapeutic targets also for adrenocortical carcinoma, a type of cancer resistant to conventional antimitotic agents.<\/jats:p>","DOI":"10.1007\/s12020-022-03074-z","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T04:02:51Z","timestamp":1652846571000},"page":"411-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["FGF\/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma"],"prefix":"10.1007","volume":"77","author":[{"given":"Mariangela","family":"Tamburello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliu","family":"Sbiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6271-5533","authenticated-orcid":false,"given":"Silviu","family":"Sbiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"issue":"2","key":"3074_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ydbio.2005.09.011","volume":"287","author":"B Thisse","year":"2005","unstructured":"B. Thisse, C. Thisse, Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287(2), 390\u2013402 (2005). https:\/\/doi.org\/10.1016\/j.ydbio.2005.09.011","journal-title":"Dev. Biol."},{"issue":"2","key":"3074_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"N. Turner, R. Grose, Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer 10(2), 116\u201329 (2010). https:\/\/doi.org\/10.1038\/nrc2780","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"3074_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2174\/156800909789057006","volume":"9","author":"M Korc","year":"2009","unstructured":"M. Korc, R.E. Friesel, The role of fibroblast growth factors in tumor growth. Curr. Cancer Drug Targets 9(5), 639\u201351 (2009). https:\/\/doi.org\/10.2174\/156800909789057006","journal-title":"Curr. Cancer Drug Targets"},{"issue":"11","key":"3074_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","volume":"20","author":"N Itoh","year":"2004","unstructured":"N. Itoh, D.M. Ornitz, Evolution of the Fgf and Fgfr gene families. Trends Genet 20(11), 563\u20139 (2004). https:\/\/doi.org\/10.1016\/j.tig.2004.08.007","journal-title":"Trends Genet"},{"issue":"6","key":"3074_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1042\/bst20180004","volume":"46","author":"B Farrell","year":"2018","unstructured":"B. Farrell, A.L. Breeze, Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem. Soc. Trans. 46(6), 1753\u201370 (2018). https:\/\/doi.org\/10.1042\/bst20180004","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"3074_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/annonc\/mdt419","volume":"25","author":"R Dienstmann","year":"2014","unstructured":"R. Dienstmann, J. Rodon, A. Prat, J. Perez-Garcia, B. Adamo, E. Felip et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 25(3), 552\u201363 (2014). https:\/\/doi.org\/10.1093\/annonc\/mdt419","journal-title":"Ann. Oncol."},{"issue":"3","key":"3074_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"D.M. Ornitz, N. Itoh, The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4(3), 215\u201366 (2015). https:\/\/doi.org\/10.1002\/wdev.176","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"issue":"2","key":"3074_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"V.P. Eswarakumar, I. Lax, J. Schlessinger, Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16(2), 139\u201349 (2005). https:\/\/doi.org\/10.1016\/j.cytogfr.2005.01.001","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"3074_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1097-2765(00)00073-3","volume":"6","author":"J Schlessinger","year":"2000","unstructured":"J. Schlessinger, A.N. Plotnikov, O.A. Ibrahimi, A.V. Eliseenkova, B.K. Yeh, A. Yayon et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6(3), 743\u201350 (2000). https:\/\/doi.org\/10.1016\/s1097-2765(00)00073-3","journal-title":"Mol. Cell"},{"issue":"2","key":"3074_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/(sici)1521-1878(200002)22:2<108::Aid-bies2>3.0.Co;2-m","volume":"22","author":"DM Ornitz","year":"2000","unstructured":"D.M. Ornitz, FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22(2), 108\u201312 (2000). https:\/\/doi.org\/10.1002\/(sici)1521-1878(200002)22:2<108::Aid-bies2>3.0.Co;2-m","journal-title":"Bioessays"},{"issue":"2","key":"3074_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0092-8674(00)00114-8","volume":"103","author":"J Schlessinger","year":"2000","unstructured":"J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 103(2), 211\u201325 (2000). https:\/\/doi.org\/10.1016\/s0092-8674(00)00114-8","journal-title":"Cell"},{"issue":"15","key":"3074_CR12","doi-asserted-by":"publisher","first-page":"8578","DOI":"10.1073\/pnas.161259898","volume":"98","author":"YR Hadari","year":"2001","unstructured":"Y.R. Hadari, N. Gotoh, H. Kouhara, I. Lax, J. Schlessinger, Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc. Natl Acad. Sci. USA 98(15), 8578\u201383 (2001). https:\/\/doi.org\/10.1073\/pnas.161259898","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"3","key":"3074_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"R. Goetz, M. Mohammadi, Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14(3), 166\u201380 (2013). https:\/\/doi.org\/10.1038\/nrm3528","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3074_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","volume":"179","author":"M Presta","year":"2017","unstructured":"M. Presta, P. Chiodelli, A. Giacomini, M. Rusnati, R. Ronca, Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharm. Ther. 179, 171\u201387 (2017). https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.013","journal-title":"Pharm. Ther."},{"issue":"2","key":"3074_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1677\/joe-06-0083","volume":"192","author":"M Haase","year":"2007","unstructured":"M. Haase, M. Schott, S.R. Bornstein, L.K. Malendowicz, W.A. Scherbaum, H.S. Willenberg, CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J. Endocrinol. 192(2), 459\u201365 (2007). https:\/\/doi.org\/10.1677\/joe-06-0083","journal-title":"J. Endocrinol."},{"issue":"3","key":"3074_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1083\/jcb.110.3.753","volume":"110","author":"AM Gonzalez","year":"1990","unstructured":"A.M. Gonzalez, M. Buscaglia, M. Ong, A. Baird, Distribution of basic fibroblast growth factor in the 18-day rat fetus: localization in the basement membranes of diverse tissues. J. Cell Biol. 110(3), 753\u201365 (1990). https:\/\/doi.org\/10.1083\/jcb.110.3.753","journal-title":"J. Cell Biol."},{"issue":"3","key":"3074_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1203\/00006450-199603000-00001","volume":"39","author":"AM Gonzalez","year":"1996","unstructured":"A.M. Gonzalez, D.J. Hill, A. Logan, P.A. Maher, A. Baird, Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatr. Res. 39(3), 375\u201385 (1996). https:\/\/doi.org\/10.1203\/00006450-199603000-00001","journal-title":"Pediatr. Res."},{"issue":"1\u20132","key":"3074_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.mce.2013.01.014","volume":"371","author":"L Guasti","year":"2013","unstructured":"L. Guasti, W.C. Candy Sze, T. McKay, R. Grose, P.J. King, FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development. Mol. Cell Endocrinol. 371(1\u20132), 182\u20138 (2013). https:\/\/doi.org\/10.1016\/j.mce.2013.01.014","journal-title":"Mol. Cell Endocrinol."},{"issue":"9","key":"3074_CR19","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1210\/endo.141.9.7632","volume":"141","author":"N Boulle","year":"2000","unstructured":"N. Boulle, C. Gicquel, A. Logi\u00e9, R. Christol, J.J. Feige, Y. Le Bouc, Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R. Endocrinology 141(9), 3127\u201336 (2000). https:\/\/doi.org\/10.1210\/endo.141.9.7632","journal-title":"Endocrinology"},{"issue":"1","key":"3074_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1677\/joe.0.1580007","volume":"158","author":"JJ Feige","year":"1998","unstructured":"J.J. Feige, I. Vilgrain, C. Brand, S. Bailly, S. Souchelnitskiy, Fine tuning of adrenocortical functions by locally produced growth factors. J. Endocrinol. 158(1), 7\u201319 (1998). https:\/\/doi.org\/10.1677\/joe.0.1580007","journal-title":"J. Endocrinol."},{"issue":"4","key":"3074_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1210\/jcem-53-4-790","volume":"53","author":"K Crickard","year":"1981","unstructured":"K. Crickard, C.R. Ill, R.B. Jaffe, Control of proliferation of human fetal adrenal cells in vitro. J. Clin. Endocrinol. Metab. 53(4), 790\u20136 (1981). https:\/\/doi.org\/10.1210\/jcem-53-4-790","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6 Pt 2","key":"3074_CR22","doi-asserted-by":"publisher","first-page":"R1253","DOI":"10.1152\/ajpregu.1993.265.6.R1253","volume":"265","author":"DP Basile","year":"1993","unstructured":"D.P. Basile, M.A. Holzwarth, Basic fibroblast growth factor may mediate proliferation in the compensatory adrenal growth response. Am. J. Physiol. 265(6 Pt 2), R1253\u201361 (1993). https:\/\/doi.org\/10.1152\/ajpregu.1993.265.6.R1253","journal-title":"Am. J. Physiol."},{"issue":"2","key":"3074_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1172\/jci108782","volume":"60","author":"PJ Hornsby","year":"1977","unstructured":"P.J. Hornsby, G.N. Gill, Hormonal control of adrenocortical cell proliferation. Desensitization to ACTH and interaction between ACTH and fibroblast growth factor in bovine adrenocortical cell cultures. J. Clin. Investig. 60(2), 342\u201352 (1977). https:\/\/doi.org\/10.1172\/jci108782","journal-title":"J. Clin. Investig."},{"key":"3074_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1749-6632.1991.tb49056.x","volume":"638","author":"C Savona","year":"1991","unstructured":"C. Savona, J.J. Feige, cAMP-mediated regulation of adrenocortical cell bFGF receptors. Ann. N. Y Acad. Sci. 638, 412\u20135 (1991). https:\/\/doi.org\/10.1111\/j.1749-6632.1991.tb49056.x","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"3","key":"3074_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1210\/er.2010-0001","volume":"32","author":"H Ishimoto","year":"2011","unstructured":"H. Ishimoto, R.B. Jaffe, Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit. Endocr. Rev. 32(3), 317\u201355 (2011). https:\/\/doi.org\/10.1210\/er.2010-0001","journal-title":"Endocr. Rev."},{"issue":"1","key":"3074_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s0039-128x(96)00161-4","volume":"62","author":"S Mesiano","year":"1997","unstructured":"S. Mesiano, R.B. Jaffe, Role of growth factors in the developmental regulation of the human fetal adrenal cortex. Steroids 62(1), 62\u201372 (1997). https:\/\/doi.org\/10.1016\/s0039-128x(96)00161-4","journal-title":"Steroids"},{"issue":"2","key":"3074_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1677\/joe.0.1160201","volume":"116","author":"FE Estivariz","year":"1988","unstructured":"F.E. Estivariz, M. Carino, P.J. Lowry, S. Jackson, Further evidence that N-terminal pro-opiomelanocortin peptides are involved in adrenal mitogenesis. J. Endocrinol. 116(2), 201\u20136 (1988). https:\/\/doi.org\/10.1677\/joe.0.1160201","journal-title":"J. Endocrinol."},{"issue":"2","key":"3074_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1677\/joe.0.1160207","volume":"116","author":"FE Estivariz","year":"1988","unstructured":"F.E. Estivariz, M.I. Morano, M. Carino, S. Jackson, P.J. Lowry, Adrenal regeneration in the rat is mediated by mitogenic N-terminal pro-opiomelanocortin peptides generated by changes in precursor processing in the anterior pituitary. J. Endocrinol. 116(2), 207\u201316 (1988). https:\/\/doi.org\/10.1677\/joe.0.1160207","journal-title":"J. Endocrinol."},{"issue":"5","key":"3074_CR29","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2002-021318","volume":"88","author":"M Fassnacht","year":"2003","unstructured":"M. Fassnacht, S. Hahner, I.A. Hansen, T. Kreutzberger, M. Zink, K. Adermann et al. N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. J. Clin. Endocrinol. Metab. 88(5), 2171\u20139 (2003). https:\/\/doi.org\/10.1210\/jc.2002-021318","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"3074_CR30","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1089\/ten.tea.2008.0305","volume":"15","author":"Y Chu","year":"2009","unstructured":"Y. Chu, W.J. Ho, J.C. Dunn, Basic fibroblast growth factor delivery enhances adrenal cortical cellular regeneration. Tissue Eng. Part A 15(8), 2093\u2013101 (2009). https:\/\/doi.org\/10.1089\/ten.tea.2008.0305","journal-title":"Tissue Eng. Part A"},{"issue":"1","key":"3074_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/endo-97-1-102","volume":"97","author":"D Gospodarowicz","year":"1975","unstructured":"D. Gospodarowicz, H.H. Handley, Stimulation of division of Y1 adrenal cells by a growth factor isolated from bovine pituitary glands. Endocrinology 97(1), 102\u20137 (1975). https:\/\/doi.org\/10.1210\/endo-97-1-102","journal-title":"Endocrinology"},{"issue":"4","key":"3074_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1210\/endo-100-4-1080","volume":"100","author":"D Gospodarowicz","year":"1977","unstructured":"D. Gospodarowicz, C.R. Ill, P.J. Hornsby, G.N. Gill, Control of bovine adrenal cortical cell proliferation by fibroblast growth factor. Lack of effect of epidermal growth factor. Endocrinology 100(4), 1080\u20139 (1977). https:\/\/doi.org\/10.1210\/endo-100-4-1080","journal-title":"Endocrinology"},{"issue":"3","key":"3074_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1677\/jme.1.01485","volume":"33","author":"AP Lepique","year":"2004","unstructured":"A.P. Lepique, M.S. Moraes, K.M. Rocha, C.B. Eichler, G.N. Hajj, T.T. Schwindt et al. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells. J. Mol. Endocrinol. 33(3), 623\u201338 (2004). https:\/\/doi.org\/10.1677\/jme.1.01485","journal-title":"J. Mol. Endocrinol."},{"issue":"3","key":"3074_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00441-011-1220-8","volume":"345","author":"GE Mattos","year":"2011","unstructured":"G.E. Mattos, J.F. Jacysyn, G.P. Amarante-Mendes, C.F. Lotfi, Comparative effect of FGF2, synthetic peptides 1-28 N-POMC and ACTH on proliferation in rat adrenal cell primary cultures. Cell Tissue Res. 345(3), 343\u201356 (2011). https:\/\/doi.org\/10.1007\/s00441-011-1220-8","journal-title":"Cell Tissue Res."},{"issue":"4","key":"3074_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3109\/07435800009048611","volume":"26","author":"CF Lotfi","year":"2000","unstructured":"C.F. Lotfi, E.T. Costa, T.T. Schwindt, H.A. Armelin, Role of ERK\/MAP kinase in mitogenic interaction between ACTH and FGF2 in mouse Y1 adrenocortical tumor cells. Endocr. Res. 26(4), 873\u20137 (2000). https:\/\/doi.org\/10.3109\/07435800009048611","journal-title":"Endocr. Res."},{"issue":"1","key":"3074_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/edrv.18.1.0292","volume":"18","author":"A Bikfalvi","year":"1997","unstructured":"A. Bikfalvi, S. Klein, G. Pintucci, D.B. Rifkin, Biological roles of fibroblast growth factor-2. Endocr. Rev. 18(1), 26\u201345 (1997). https:\/\/doi.org\/10.1210\/edrv.18.1.0292","journal-title":"Endocr. Rev."},{"issue":"2","key":"3074_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","volume":"16","author":"M Presta","year":"2005","unstructured":"M. Presta, P. Dell\u2019Era, S. Mitola, E. Moroni, R. Ronca, M. Rusnati, Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16(2), 159\u201378 (2005). https:\/\/doi.org\/10.1016\/j.cytogfr.2005.01.004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"3074_CR38","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1210\/endo-117-6-2383","volume":"117","author":"D Gospodarowicz","year":"1985","unstructured":"D. Gospodarowicz, J. Cheng, G.M. Lui, A. Baird, F. Esch, P. Bohlen, Corpus luteum angiogenic factor is related to fibroblast growth factor. Endocrinology 117(6), 2383\u201391 (1985). https:\/\/doi.org\/10.1210\/endo-117-6-2383","journal-title":"Endocrinology"},{"issue":"3","key":"3074_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1210\/edrv.18.3.0304","volume":"18","author":"S Mesiano","year":"1997","unstructured":"S. Mesiano, R.B. Jaffe, Developmental and functional biology of the primate fetal adrenal cortex. Endocr. Rev. 18(3), 378\u2013403 (1997). https:\/\/doi.org\/10.1210\/edrv.18.3.0304","journal-title":"Endocr. Rev."},{"issue":"1","key":"3074_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0169-328x(95)00246-o","volume":"36","author":"C Meisinger","year":"1996","unstructured":"C. Meisinger, A. Hertenstein, C. Grothe, Fibroblast growth factor receptor 1 in the adrenal gland and PC12 cells: developmental expression and regulation by extrinsic molecules. Brain Res. Mol. Brain Res. 36(1), 70\u20138 (1996). https:\/\/doi.org\/10.1016\/0169-328x(95)00246-o","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"6","key":"3074_CR41","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/j.1460-2075.1991.tb07654.x","volume":"10","author":"J Partanen","year":"1991","unstructured":"J. Partanen, T.P. M\u00e4kel\u00e4, E. Eerola, J. Korhonen, H. Hirvonen, L. Claesson-Welsh et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. Embo J. 10(6), 1347\u201354 (1991)","journal-title":"Embo J."},{"issue":"7","key":"3074_CR42","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/002215549704500710","volume":"45","author":"SE Hughes","year":"1997","unstructured":"S.E. Hughes, Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45(7), 1005\u201319 (1997). https:\/\/doi.org\/10.1177\/002215549704500710","journal-title":"J. Histochem. Cytochem."},{"key":"3074_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2015.06.022","volume":"413","author":"R H\u00e4fner","year":"2015","unstructured":"R. H\u00e4fner, T. Bohnenpoll, C. Rudat, T.M. Schultheiss, A. Kispert, Fgfr2 is required for the expansion of the early adrenocortical primordium. Mol. Cell Endocrinol. 413, 168\u201377 (2015). https:\/\/doi.org\/10.1016\/j.mce.2015.06.022","journal-title":"Mol. Cell Endocrinol."},{"key":"3074_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mce.2006.12.028","volume":"265-266","author":"AC Kim","year":"2007","unstructured":"A.C. Kim, G.D. Hammer, Adrenocortical cells with stem\/progenitor cell properties: recent advances. Mol. Cell Endocrinol. 265-266, 10\u20136 (2007). https:\/\/doi.org\/10.1016\/j.mce.2006.12.028","journal-title":"Mol. Cell Endocrinol."},{"issue":"1","key":"3074_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15332-7","volume":"11","author":"S Leng","year":"2020","unstructured":"S. Leng, E. Pignatti, R.S. Khetani, M.S. Shah, S. Xu, J. Miao et al. \u03b2-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. Nat. Commun. 11(1), 1680 (2020). https:\/\/doi.org\/10.1038\/s41467-020-15332-7","journal-title":"Nat. Commun."},{"issue":"1","key":"3074_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrendo.2014.166","volume":"11","author":"EM Walczak","year":"2015","unstructured":"E.M. Walczak, G.D. Hammer, Regulation of the adrenocortical stem cell niche: implications for disease. Nat. Rev. Endocrinol. 11(1), 14\u201328 (2015). https:\/\/doi.org\/10.1038\/nrendo.2014.166","journal-title":"Nat. Rev. Endocrinol."},{"key":"3074_CR47","doi-asserted-by":"publisher","unstructured":"I. Sbiera, S. Kircher, B. Altieri, M. Fassnacht, M. Kroiss, S. Sbiera, Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues? Cancers (Basel).13(7), (2021). https:\/\/doi.org\/10.3390\/cancers13071736.","DOI":"10.3390\/cancers13071736"},{"issue":"2","key":"3074_CR48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ecl.2015.02.001","volume":"44","author":"Y Xing","year":"2015","unstructured":"Y. Xing, A.M. Lerario, W. Rainey, G.D. Hammer, Development of adrenal cortex zonation. Endocrinol. Metab. Clin. North Am. 44(2), 243\u201374 (2015). https:\/\/doi.org\/10.1016\/j.ecl.2015.02.001","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"1","key":"3074_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/dbio.2000.0144","volume":"231","author":"JM Revest","year":"2001","unstructured":"J.M. Revest, B. Spencer-Dene, K. Kerr, L. De Moerlooze, I. Rosewell, C. Dickson, Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev. Biol. 231(1), 47\u201362 (2001). https:\/\/doi.org\/10.1006\/dbio.2000.0144","journal-title":"Dev. Biol."},{"key":"3074_CR50","doi-asserted-by":"crossref","unstructured":"M.E. Pownall, H. V. Isaacs, Developmental Biology. FGF Signalling in Vertebrate Development. (Morgan & Claypool Life Sciences. Copyright \u00a9 2010 by Morgan & Claypool Life Sciences, San Rafael (CA), 2010).","DOI":"10.4199\/C00011ED1V01Y201004DEB002"},{"issue":"5","key":"3074_CR51","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"M.A. Krook, J.W. Reeser, G. Ernst, H. Barker, M. Wilberding, G. Li et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124(5), 880\u201392 (2021). https:\/\/doi.org\/10.1038\/s41416-020-01157-0","journal-title":"Br. J. Cancer"},{"issue":"3","key":"3074_CR52","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","volume":"34","author":"T Helsten","year":"2015","unstructured":"T. Helsten, M. Schwaederle, R. Kurzrock, Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 34(3), 479\u201396 (2015). https:\/\/doi.org\/10.1007\/s10555-015-9579-8","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"3074_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.Ccr-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"T. Helsten, S. Elkin, E. Arthur, B.N. Tomson, J. Carter, R. Kurzrock, The FGFR Landscape in Cancer: analysis of 4853 Tumors by Next-Generation Sequencing. Clin. Cancer Res. 22(1), 259\u201367 (2016). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-3212","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"3074_CR54","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","volume":"40","author":"L Chen","year":"2021","unstructured":"L. Chen, Y. Zhang, L. Yin, B. Cai, P. Huang, X. Li et al. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J. Exp. Clin. Cancer Res. 40(1), 345 (2021). https:\/\/doi.org\/10.1186\/s13046-021-02156-6","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"3074_CR55","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1517\/14728222.2015.1062475","volume":"19","author":"R Ronca","year":"2015","unstructured":"R. Ronca, A. Giacomini, M. Rusnati, M. Presta, The potential of fibroblast growth factor\/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin. Ther. Targets 19(10), 1361\u201377 (2015). https:\/\/doi.org\/10.1517\/14728222.2015.1062475","journal-title":"Expert Opin. Ther. Targets"},{"issue":"19","key":"3074_CR56","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","volume":"17","author":"C Lieu","year":"2011","unstructured":"C. Lieu, J. Heymach, M. Overman, H. Tran, S. Kopetz, Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 17(19), 6130\u20139 (2011). https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0659","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"3074_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","volume":"16","author":"R Grose","year":"2005","unstructured":"R. Grose, C. Dickson, Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16(2), 179\u201386 (2005). https:\/\/doi.org\/10.1016\/j.cytogfr.2005.01.003","journal-title":"Cytokine Growth Factor Rev."},{"key":"3074_CR58","doi-asserted-by":"publisher","unstructured":"A. Kommalapati, S.H. Tella, M. Borad, M. Javle, A. Mahipal, FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel).13(12), (2021). https:\/\/doi.org\/10.3390\/cancers13122968.","DOI":"10.3390\/cancers13122968"},{"issue":"5","key":"3074_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"S. Zheng, A.D. Cherniack, N. Dewal, R.A. Moffitt, L. Danilova, B.A. Murray et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29(5), 723\u201336 (2016). https:\/\/doi.org\/10.1016\/j.ccell.2016.04.002","journal-title":"Cancer Cell"},{"issue":"1","key":"3074_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mce.2011.09.044","volume":"351","author":"G Assie","year":"2012","unstructured":"G. Assie, T.J. Giordano, J. Bertherat, Gene expression profiling in adrenocortical neoplasia. Mol. Cell Endocrinol. 351(1), 111\u20137 (2012). https:\/\/doi.org\/10.1016\/j.mce.2011.09.044","journal-title":"Mol. Cell Endocrinol."},{"issue":"7","key":"3074_CR61","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/jco.2008.18.5678","volume":"27","author":"A de Reyni\u00e8s","year":"2009","unstructured":"A. de Reyni\u00e8s, G. Assi\u00e9, D.S. Rickman, F. Tissier, L. Groussin, F. Ren\u00e9-Corail et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27(7), 1108\u201315 (2009). https:\/\/doi.org\/10.1200\/jco.2008.18.5678","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"3074_CR62","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","volume":"34","author":"B Altieri","year":"2020","unstructured":"B. Altieri, C.L. Ronchi, M. Kroiss, M. Fassnacht, Next-generation therapies for adrenocortical carcinoma. Best. Pr. Res Clin. Endocrinol. Metab. 34(3), 101434 (2020). https:\/\/doi.org\/10.1016\/j.beem.2020.101434","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"9","key":"3074_CR63","doi-asserted-by":"publisher","first-page":"e73959","DOI":"10.1371\/journal.pone.0073959","volume":"8","author":"CL Ronchi","year":"2013","unstructured":"C.L. Ronchi, S. Sbiera, E. Leich, K. Henzel, A. Rosenwald, B. Allolio et al. Single nucleotide polymorphism array profiling of adrenocortical tumors\u2013evidence for an adenoma carcinoma sequence? PLoS ONE 8(9), e73959 (2013). https:\/\/doi.org\/10.1371\/journal.pone.0073959","journal-title":"PLoS ONE"},{"issue":"10","key":"3074_CR64","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1210\/jc.2013-2165","volume":"98","author":"MC De Martino","year":"2013","unstructured":"M.C. De Martino, A. Al Ghuzlan, S. Aubert, G. Assi\u00e9, J.Y. Scoazec, S. Leboulleux et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J. Clin. Endocrinol. Metab. 98(10), 4080\u20138 (2013). https:\/\/doi.org\/10.1210\/jc.2013-2165","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3074_CR65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"T.J. Giordano, D.G. Thomas, R. Kuick, M. Lizyness, D.E. Misek, A.L. Smith et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162(2), 521\u201331 (2003). https:\/\/doi.org\/10.1016\/s0002-9440(10)63846-1","journal-title":"Am. J. Pathol."},{"issue":"3","key":"3074_CR66","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1210\/jc.2004-1075","volume":"90","author":"F de Fraipont","year":"2005","unstructured":"F. de Fraipont, M. El Atifi, N. Cherradi, G. Le Moigne, G. Defaye, R. Houlgatte et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 90(3), 1819\u201329 (2005). https:\/\/doi.org\/10.1210\/jc.2004-1075","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3074_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1530\/EJE-09-0068","volume":"161","author":"C Laurell","year":"2009","unstructured":"C. Laurell, D. Vel\u00e1zquez-Fern\u00e1ndez, K. Lindsten, C. Juhlin, U. Enberg, J. Geli et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur. J. Endocrinol. 161(1), 141\u201352 (2009). https:\/\/doi.org\/10.1530\/EJE-09-0068","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3074_CR68","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/0008-5472.Can-06-3767","volume":"67","author":"AN West","year":"2007","unstructured":"A.N. West, G.A. Neale, S. Pounds, B.C. Figueredo, C. Rodriguez Galindo, M.A. Pianovski et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 67(2), 600\u20138 (2007). https:\/\/doi.org\/10.1158\/0008-5472.Can-06-3767","journal-title":"Cancer Res."},{"issue":"3","key":"3074_CR69","doi-asserted-by":"publisher","first-page":"L11","DOI":"10.1530\/ERC-11-0231","volume":"19","author":"LP Brito","year":"2012","unstructured":"L.P. Brito, T.C. Ribeiro, M.Q. Almeida, A.A. Jorge, I.C. Soares, A.C. Latronico et al. The role of fibroblast growth factor receptor 4 overexpression and gene amplification as prognostic markers in pediatric and adult adrenocortical tumors. Endocr. Relat. Cancer 19(3), L11\u20133 (2012). https:\/\/doi.org\/10.1530\/ERC-11-0231","journal-title":"Endocr. Relat. Cancer"},{"key":"3074_CR70","doi-asserted-by":"publisher","first-page":"795116","DOI":"10.3389\/fendo.2021.795116","volume":"12","author":"I Sbiera","year":"2021","unstructured":"I. Sbiera, S. Kircher, B. Altieri, K. Lenz, C. Hantel, M. Fassnacht et al. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Front. Endocrinol. (Lausanne) 12, 795116 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.795116","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"3074_CR71","doi-asserted-by":"publisher","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","volume":"7","author":"P Krejci","year":"2012","unstructured":"P. Krejci, A. Aklian, M. Kaucka, E. Sevcikova, J. Prochazkova, J.K. Masek et al. Receptor tyrosine kinases activate canonical WNT\/\u03b2-catenin signaling via MAP kinase\/LRP6 pathway and direct \u03b2-catenin phosphorylation. PLoS ONE 7(4), e35826 (2012). https:\/\/doi.org\/10.1371\/journal.pone.0035826","journal-title":"PLoS ONE"},{"issue":"3","key":"3074_CR72","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1210\/jc.2014-3282","volume":"100","author":"CC Juhlin","year":"2015","unstructured":"C.C. Juhlin, G. Goh, J.M. Healy, A.L. Fonseca, U.I. Scholl, A. Stenman et al. Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab. 100(3), E493\u2013E502 (2015). https:\/\/doi.org\/10.1210\/jc.2014-3282","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3074_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-020-05110-5","volume":"13","author":"M Haase","year":"2020","unstructured":"M. Haase, A. Thiel, U.I. Scholl, H. Ashmawy, M. Schott, M. Ehlers, Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma. BMC Res. Notes 13(1), 282 (2020). https:\/\/doi.org\/10.1186\/s13104-020-05110-5","journal-title":"BMC Res. Notes"},{"issue":"4","key":"3074_CR74","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbamcr.2012.01.004","volume":"1823","author":"I Ahmad","year":"2012","unstructured":"I. Ahmad, T. Iwata, H.Y. Leung, Mechanisms of FGFR-mediated carcinogenesis. Biochim. Biophys. Acta 1823(4), 850\u201360 (2012). https:\/\/doi.org\/10.1016\/j.bbamcr.2012.01.004","journal-title":"Biochim. Biophys. Acta"},{"key":"3074_CR75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.phrs.2016.03.024","volume":"107","author":"A Giacomini","year":"2016","unstructured":"A. Giacomini, P. Chiodelli, S. Matarazzo, M. Rusnati, M. Presta, R. Ronca, Blocking the FGF\/FGFR system as a \u201ctwo-compartment\u201d antiangiogenic\/antitumor approach in cancer therapy. Pharm. Res. 107, 172\u201385 (2016). https:\/\/doi.org\/10.1016\/j.phrs.2016.03.024","journal-title":"Pharm. Res."},{"issue":"3","key":"3074_CR76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.Cd-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"M.V. Dieci, M. Arnedos, F. Andre, J.C. Soria, Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Disco. 3(3), 264\u201379 (2013). https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0362","journal-title":"Cancer Disco."},{"issue":"9","key":"3074_CR77","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Y.K. Chae, K. Ranganath, P.S. Hammerman, C. Vaklavas, N. Mohindra, A. Kalyan et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 8(9), 16052\u201374 (2017). https:\/\/doi.org\/10.18632\/oncotarget.14109","journal-title":"Oncotarget"},{"issue":"3","key":"3074_CR78","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/med.0000000000000247","volume":"23","author":"B Konda","year":"2016","unstructured":"B. Konda, L.S. Kirschner, Novel targeted therapies in adrenocortical carcinoma. Curr. Opin. Endocrinol. Diabetes Obes. 23(3), 233\u201341 (2016). https:\/\/doi.org\/10.1097\/med.0000000000000247","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"3074_CR79","doi-asserted-by":"publisher","unstructured":"J. Garc\u00eda-Donas, S. Hernando Polo, M. Guix, M.A. Climent Duran, M.J. M\u00e9ndez-Vidal, P. Jim\u00e9nez-Fonseca, et al. Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03. Journal of Clinical Oncology 32(15_suppl):4588-4588 (2014). https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.4588","DOI":"10.1200\/jco.2014.32.15_suppl.4588"},{"issue":"11","key":"3074_CR80","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/bjc.2017.330","volume":"117","author":"KP Papadopoulos","year":"2017","unstructured":"K.P. Papadopoulos, B.F. El-Rayes, A.W. Tolcher, A. Patnaik, D.W. Rasco, R.D. Harvey et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br. J. Cancer 117(11), 1592\u20139 (2017). https:\/\/doi.org\/10.1038\/bjc.2017.330","journal-title":"Br. J. Cancer"},{"issue":"1","key":"3074_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"M. Katoh, FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J. Mol. Med. 38(1), 3\u201315 (2016). https:\/\/doi.org\/10.3892\/ijmm.2016.2620","journal-title":"Int J. Mol. Med."},{"issue":"9","key":"3074_CR82","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14737140.2018.1491795","volume":"18","author":"GC Ghedini","year":"2018","unstructured":"G.C. Ghedini, R. Ronca, M. Presta, A. Giacomini, Future applications of FGF\/FGFR inhibitors in cancer. Expert Rev. Anticancer Ther. 18(9), 861\u201372 (2018). https:\/\/doi.org\/10.1080\/14737140.2018.1491795","journal-title":"Expert Rev. Anticancer Ther."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03074-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03074-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03074-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T15:30:17Z","timestamp":1660750217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03074-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03074-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}